Skip to main content
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Inc. — Investor Relations & Filings

Ticker · ERNA ISIN · US6294106066 US Manufacturing
Filings indexed 1,027 across all filing types
Latest filing 2025-05-14 Major Shareholding Noti…
Country US United States of America
Listing US ERNA

About Ernexa Therapeutics Inc.

https://www.ernexatx.com/

Ernexa Therapeutics Inc. is a biopharmaceutical company developing cell therapies for advanced cancer and autoimmune diseases. The company's core technology platform engineers induced pluripotent stem cells (iPSCs) and differentiates them into induced mesenchymal stem cells (iMSCs). These engineered iMSCs are designed as scalable, off-the-shelf treatments that leverage the natural ability of MSCs to home to sites of tumors or inflammation. Once at the target site, the cells deliver therapeutic payloads, such as cytokines, to modulate the immune system. The company's lead candidate, ERNA-101, is being developed for the treatment of ovarian cancer. Its pipeline also includes ERNA-201, a cell therapy designed to target inflammation in autoimmune diseases.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-14 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-05-07 English
Regulatory Filings 2025
Regulatory Filings
2025-04-30 English
PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) under the Securities Act of 1933. It details the registration of shares for resale by selling stockholders, including information about a private placement, registration rights agreement, and resale of shares. The document includes sections such as Risk Factors, Use of Proceeds, Selling Stockholders, and Plan of Distribution. It is not a financial report, earnings release, or management discussion, but rather a registration statement prospectus related to capital raising and share resale. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length (15,000 characters) and detailed content confirm it is the actual prospectus, not just an announcement. Therefore, the correct classification is CAP with high confidence.
2025-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.